UK Cosmetics Compliance After Brexit: Why EU Approval No Longer Travels

Between 2021 and today, we’ve seen a frustrating pattern repeat itself: a European cosmetics brand — confident in its EU dossier, its CPNP notifications, its signed-off safety reports — discovers mid-shipment that its product is technically non-compliant the moment it enters Great Britain. Not because of a formulation error. Not because a preservative slipped through. Because the label carried a Paris address where a London or Manchester address was now legally required.

Brexit didn’t invent a new cosmetics regulation from scratch. What it did was create a parallel system — one that, in 2026, is quietly growing further apart from EU Regulation (EC) No 1223/2009 with each passing amendment cycle. For European brands with UK retail partnerships or export ambitions, that gap is now wide enough to cause real, traceable compliance failures.

Here’s what’s actually different, and what you need to have in place before your next UK shipment.

What Brexit Did to UK Cosmetics Law — And What It Didn’t

The United Kingdom retained EU Regulation (EC) No 1223/2009 into domestic law via the European Union (Withdrawal) Act 2018. So when the transition period closed on 31 December 2020, Great Britain didn’t start from a blank page. The fundamental architecture — Annexes I through VI, the Responsible Person model, the Product Information File, safety assessment requirements, CPNP-style notifications — all of it carried over verbatim.

But retained law is not frozen law. Since January 2021, the UK government has held the authority to amend its own version of the cosmetics regulation, and it has been using that authority. Slowly at first. Then with increasing frequency. The result is what regulators call regulatory divergence: two frameworks sharing a common ancestor but gradually moving apart.

The primary enforcement body in Great Britain is the Office for Product Safety and Standards (OPSS), an executive agency of the Department for Business and Trade. It carries out market surveillance, investigates safety incidents, and coordinates with Trading Standards authorities at the local level. OPSS inspections are not a theoretical risk for brands distributing at scale in the UK — they happen.

For any European brand that complied with EU Regulation 1223/2009 in 2020 and has simply assumed that compliance still covers the UK market, the drift now matters in practical, costly ways.

The Three Requirements You Cannot Carry Over From Your EU Dossier

A UK-Based Responsible Person

This is where most European brands trip first. Under EU Regulation 1223/2009, a product placed on the EU market must have a Responsible Person (RP) established within the EU. That EU-based RP is simply not valid for the GB market.

For products sold in Great Britain, the Responsible Person must be established in the UK — meaning England, Scotland, or Wales. You cannot appoint your existing French or German RP to cover both territories. You need a separate UK-registered entity to act as RP, or you need to formally appoint a UK-based representative service that takes on that legal function.

And it’s not purely a labelling issue. The UK Responsible Person bears statutory responsibility for product safety, SCPN notifications, serious undesirable effect (SUE) reporting under UK law, and cooperation with OPSS during enforcement actions. Placing a non-UK entity in that role isn’t a minor technicality — it leaves the product without a legally valid RP in the eyes of British regulators, which is a prima facie compliance failure.

SCPN Registration — Not CPNP

The EU’s Cosmetic Products Notification Portal (CPNP) was replaced for the GB market by SCPN: the Submit Cosmetic Product Notification system, operated by OPSS. These are entirely separate databases with no cross-reference between them. A complete, accepted notification on the EU’s CPNP does absolutely nothing for GB compliance.

Every cosmetic product placed on the GB market must be notified via SCPN before it is made available to consumers. The notification requires: product name and category, full INCI formulation with concentrations, name and UK address of the Responsible Person, country of manufacture, and the original frame formulation reference where applicable.

If you’ve been selling into the UK via a distributor who was handling compliance “somehow,” now is a good moment to ask exactly how — and to request the SCPN notification references. Because that paper trail, or its absence, is visible the moment OPSS opens an inspection file.

UK-Compliant Labelling

The label on your EU-approved product almost certainly doesn’t meet UK requirements. The mandatory particulars are structurally similar to what you know from the EU — product name, nominal content, durability indication, special precautions, batch number, function, ingredient list — but the UK version requires the UK Responsible Person’s name and UK address, not the EU RP’s. All mandatory warnings and directions of use must appear in English.

This has real production implications. If you’re running a single batch intended for both EU and UK distribution, you either need two label variants — one per territory — or a dual-compliant label engineered to satisfy both sets of requirements simultaneously. That’s achievable with careful planning, but it has to be planned. It doesn’t happen by default.

Where UK and EU Rules Have Already Diverged

Beyond the administrative requirements, there are now genuine technical divergences affecting formulation. These are the ones that matter most to product developers and regulatory affairs teams.

Fragrance Allergens: A Concrete Split

The EU amended Annex III to Regulation (EC) No 1223/2009 via Regulation (EU) 2023/1545, adding 56 new fragrance substances to the list requiring on-label disclosure. The amendment also tightened the concentration thresholds for several existing entries. EU brands — particularly French perfumers and skincare formulators — had to adapt both formulations and labels to comply.

The UK has not mirrored this amendment. Its Annex III still reflects the pre-2023 list. This means a fragrance blend that triggers a mandatory allergen declaration in Germany may require no such disclosure on a UK label. And if you’re using a single formulation across both markets, you’re holding yourself to the stricter EU standard by default — which is the right call from a safety standpoint, but you should be making it deliberately rather than discovering it during a UK labelling audit.

Titanium Dioxide in Powder Products

The EU prohibited titanium dioxide (TiO2) in powder-form cosmetic products where inhalation exposure during intended use is reasonably foreseeable. This came via an amendment to Annex II, with application from 1 October 2021 for new products placed on the EU market. Loose finishing powders, dry eyeshadow palettes, and aerosol-format products were the primary affected categories — TiO2 is widely used as an opacifying agent and white pigment in these formats.

The UK has not implemented an equivalent restriction. TiO2 in powder cosmetics remains permitted on the GB market. If you reformulated an EU-facing product to remove TiO2 — and many brands did — that reformulation may not be necessary for UK compliance. It’s not harmful to apply the stricter standard universally, but managing two formulation variants of the same product carries its own cost and quality assurance complexity that brands need to account for deliberately.

CMR Substances: Slow but Ongoing Divergence

The EU’s automatic restriction of substances classified as carcinogenic, mutagenic, or toxic to reproduction (CMR) under Annex II is a living list. It updates as EU chemical classification evolves under the CLP Regulation, (EC) No 1272/2008. The UK now maintains its own CMR classification framework under UK REACH, which is diverging from its EU counterpart. In practice, this means the set of substances that trigger automatic cosmetics restrictions in each territory is drifting further apart each year. The gap is still manageable in 2026. In five years, it may require separate Annex II compliance reviews for each market.

Northern Ireland: The Third Regime

Northern Ireland deserves specific attention because it operates under a genuinely distinct framework resulting from the Windsor Framework.

For cosmetics, this means products placed on the Northern Ireland market must comply with EU Regulation (EC) No 1223/2009 — including EU CPNP notification and an EU-based Responsible Person. Labelling must meet EU requirements. From a goods-regulation standpoint, Northern Ireland’s consumers are in the EU single market.

For European brands, Northern Ireland is actually the easiest market to manage: your existing EU dossier, CPNP notification, and EU-based RP already cover it. No additional UK-specific compliance work is needed for NI distribution.

But — and this catches some brands out — you cannot use your NI-compliant documentation as a route into the GB market. The two systems are not interchangeable, and OPSS does not recognise EU CPNP notifications as fulfilling the SCPN requirement for GB. If you’re shipping product from a European warehouse to both Belfast and Birmingham, they are two different compliance exercises.

What European Brands Actually Need in 2026

If you’re a European cosmetics manufacturer — a French skincare house, an Italian fragrance brand, a German wellness company — and you want to place products on GB shelves this year, the minimum viable compliance stack looks like this:

• A UK Responsible Person established in Great Britain, formally designated and named on the label
• SCPN notification completed for every product in your GB-facing range, before first placement on the market
• UK-compliant labels with the UK RP address and English-language mandatory particulars
• A formulation review against current UK Annexes II and III, specifically cross-checking against the 2023 EU fragrance allergen update and the TiO2 powder restriction — neither of which the UK has adopted, meaning your EU-adapted formulas may differ from what’s optimal for the UK market

None of this is technically complex. What makes it costly is discovering it late — after 50,000 units are printed with a Paris address on the back panel, or after a UK distributor is asked by OPSS to produce SCPN reference numbers during a routine inspection and can’t.

The UK remains Europe’s second-largest cosmetics market, with annual retail sales estimated at over £11 billion. For European brands building an export strategy that includes British retailers, the market is clearly worth the effort. But it requires a genuinely separate compliance effort — not an assumption that Brussels approval travels to London.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• FDA Compliance Testing for European Cosmetics Exporters — US market entry requirements under MoCRA, ISO 17025 testing, and FDA facility registration for European brands
• Health Canada Cosmetics Compliance for European Brands — Canadian market requirements, from ingredient notifications to bilingual labelling, for European manufacturers entering North America